Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.90 and traded as low as $0.85. Seres Therapeutics shares last traded at $0.88, with a volume of 1,720,972 shares trading hands.
Analyst Ratings Changes
MCRB has been the topic of several recent research reports. JPMorgan Chase & Co. cut shares of Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Thursday, October 24th. StockNews.com downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, November 27th. Canaccord Genuity Group reissued a "buy" rating and set a $10.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 14th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $1.25 target price on shares of Seres Therapeutics in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $5.08.
Get Our Latest Report on Seres Therapeutics
Seres Therapeutics Price Performance
The company has a 50-day moving average of $0.79 and a 200 day moving average of $0.89. The company has a market cap of $146.83 million, a PE ratio of -3.74 and a beta of 2.07.
Hedge Funds Weigh In On Seres Therapeutics
Large investors have recently modified their holdings of the stock. Virtu Financial LLC boosted its stake in shares of Seres Therapeutics by 44.8% during the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 18,191 shares during the period. Providence Wealth Advisors LLC boosted its position in shares of Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company's stock valued at $58,000 after buying an additional 25,250 shares during the period. Point72 DIFC Ltd purchased a new position in shares of Seres Therapeutics during the second quarter valued at approximately $64,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Seres Therapeutics during the second quarter valued at approximately $92,000. Finally, State Street Corp raised its holdings in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock worth $363,000 after buying an additional 43,700 shares during the period. Institutional investors own 59.34% of the company's stock.
Seres Therapeutics Company Profile
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
See Also
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
